Articles for Physicians - Articles by DoctorsMedical Articles › Big Pharmas Vying for Product Specific Deals in Global RNAi Industry

   As per our new research report “Global RNAi Market Analysis”, companies working in the RNAi industry are presently interested in a specific RNAi Therapeutics candidate with which they can deal with the external company directly, without the need for an in-house middleman. Our study indicates that, many companies have started looking for this option. For instance, Pfizer has already pursued this alternative pathway as they have partnered the ddRNAi program for HCV with Tacere and a synthetic siRNA candidate from Quark for wet AMD. In both the cases, there seemed to have been little involvement by Pfizer’s in-house oligonucleotide therapeutics unit.

   Further, recently Marina Biotech announced a product-specific development deal with Swiss drug licensing and development company Debiopharm that covers a pre-clinical stage RNAi Therapeutics program for bladder cancer (via topical LNP-siRNA administration), where much of the early development work will stay with Marina.

   Additionally, we have done a thorough and prudent analysis of the global RNAi industry. We have identified that, RNAi is already an established enabling biotechnology product platform and its use in therapeutics and diagnostics may rival products, like recombinant proteins or monoclonal antibodies in future. It is anticipated that, the global RNAi market will grow at a CAGR of around 28% during 2010-2015.

   Besides, our study indicates that, presently in the nascent stages, the RNAi industry is gaining ground in the therapeutics arena, with its most promising application being high-throughput screening. The first of the approved RNAi-based drugs are expected to foray into the therapeutics market in 2013.

   Further, the US and Europe together account for a lion's share of the global RNAi market. However, research and investments around the globe have spurred the industry performance to a great extent. The governments in various Asian countries, such as Japan, China, India, and Korea have made huge investments for the growth and development of RNAi research in their respective countries.

   “Global RNAi Market Analysis” provides thorough research and rational analysis along with reliable statistics of the global RNAi industry. The report provides extensive information and rational analysis of the global RNAi market. It has thoroughly examined market applications, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in coming years. The report also provides an insight into the different products available in the market on a segment level. Besides, the research contains exhaustive information regarding recent developments in the geographical markets that will help clients in formulating market strategies and assess opportunity areas in the global RNAi market.

About RNCOS:

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals study and analyze the industry and its various components, with comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the consultants in meeting their objectives in a cost-effective and timely manner.

Article By: Shushmul Maheshwari

Comments On Big Pharmas Vying for Product Specific Deals in Global RNAi Industry

Your Comment
Your Name
Your Email

Your Email will not be shown with your comment

Secret Number

Please type the numbers shown above into the Secret Number box.